[1]张玉香,顾志荣,李钦,等.七十味珍珠丸抗阿尔兹海默病的临床应用、药理作用及其机制研究进展[J].西部中医药,2023,36(08):157-161.[doi:10.12174/j.issn.2096-9600.2023.08.38]
ZHANG Yuxiang,GU Zhirong,LI Qin,et al.Research Progress on Clinical Application, Pharmacological Effect and the Mechanism of Ratnasampil Against Alzheimer′s Disease[J].Western Journal of Traditional Chinese Medicine,2023,36(08):157-161.[doi:10.12174/j.issn.2096-9600.2023.08.38]
点击复制
七十味珍珠丸抗阿尔兹海默病的临床应用、药理作用及其机制研究进展
《西部中医药》[ISSN:2096-9600/CN:62-1204/R]
- 卷:
-
36
- 期数:
-
2023年08期
- 页码:
-
157-161
- 栏目:
-
- 出版日期:
-
2023-08-15
文章信息/Info
- Title:
-
Research Progress on Clinical Application, Pharmacological Effect and the Mechanism of Ratnasampil Against Alzheimer′s Disease
- 作者:
-
张玉香1, 顾志荣2, 李钦1, 吴国泰3, 李海龙3, 李芳3
-
1.甘肃卫生职业学院,甘肃 兰州 730207
2.甘肃省人民医院,甘肃 兰州 730000
3.甘肃中医药大学,甘肃 兰州 730000
- Author(s):
-
ZHANG Yuxiang1, GU Zhirong2, LI Qin1, WU Guotai3, LI Hailong3, LI Fang3
-
1.Gansu Province Health School, Lanzhou 730207, China
2.Gansu Provincial Hospital, Lanzhou 730000, China
3.Gansu University of Chinese Medicine, Lanzhou 730000, China
-
- 关键词:
-
阿尔兹海默病; 七十味珍珠丸; 临床研究; 药理研究; 作用机制
- Keywords:
-
Alzheimer's disease; Ratnasampil; clinical study; pharmacological study; mechanism
- 分类号:
-
R322.81
- DOI:
-
10.12174/j.issn.2096-9600.2023.08.38
- 文献标志码:
-
A
- 摘要:
-
藏药七十味珍珠丸(Tibetan medicine ratnasampil,RNSP)是预防和治疗阿尔兹海默病(Alzheimer′s disease,AD)的前景药物,对防治轻、中度AD具有很好的临床应用价值。RNSP能显著改善轻、中度AD患者的认知功能和日常生活自理能力,具有改善记忆、修复大脑神经元、提高学习记忆能力、改善大脑氧化应激(oxidative stress,OS)水平等药理作用。RNSP抗AD的机制可能是通过保护神经,降低大脑中和AD相关的β淀粉样蛋白(amyloid,Aβ)水平,抵抗大脑慢性炎症,减少炎症因子激活及抗OS等产生的。建议开展较大规模的多中心随机对照双盲实验,进一步确定RNSP预防和治疗AD的临床价值,并在分子和基因水平加强其药理机制探讨。
- Abstract:
-
Tibetan medicine Ratnasampil (RNSP) is a prospective drug for the prevention and treatment of Alzheimer's disease (AD), and it has good clinical application value for the prevention and treatment of mild to moderate AD. RNSP can significantly improve mild to moderate AD patients' cognitive function and self-care ability in daily life owing to its pharmacological effects of improving memory, repairing brain neurons, improving learning and memorization skills and the levels of cerebral oxidative stress. Its mechanism of anti-AD might be realized by protecting nerves, reducing the expressions of AD-related amyloid (Aβ) in the brain, resisting chronic inflammation of the brain, reducing inflammatory factors activation and anti-oxidative stress (OS). Therefore, larger scale multicenter randomized controlled double-blind trials should be recommended in order to further ensure its clinical value in the prevention and treatment of AD, and its pharmacological mechanism should be discussed at the molecular and genetic levels.
备注/Memo
- 备注/Memo:
-
张玉香(1982—),女,讲师,硕士学位。研究方向:精神心理疾病的中西医结合治疗。国家自然科学基金青年基金(81804081);成都中医药大学“杏林学者”学科人科研提升计划项目(QNXZ2019012)。 国家自然科学基金(81960828);甘肃省教育厅高等学校科研项目(2018A-042);甘肃中医药大学方剂学重点实验室基金项目(ZYFYZH-KJ-2016-2005)
更新日期/Last Update:
2023-08-15